Thyrotropin Alfa
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Thyrotropin Alfa: From Thyroid Cancer Follow-Up to Migraine Disorder
One-Sentence Summary
Thyrotropin alfa (recombinant human TSH) is used as a diagnostic aid in the follow-up of well-differentiated thyroid cancer, stimulating thyroid tissue to raise thyroglobulin levels and radioiodine uptake. The TxGNN model predicts a possible link to Migraine Disorder, but this prediction is currently supported by no clinical trials and no relevant literature — it is a model output only.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Thyroid cancer follow-up (adjunctive diagnostic use to stimulate thyroglobulin/radioiodine uptake) |
| Predicted New Indication | Migraine Disorder |
| TxGNN Prediction Score | 99.98% |
| Evidence Level | L5 |
| Denmark Market Status | Not marketed |
| Number of Marketing Authorisations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data for thyrotropin alfa is not currently available in this evidence pack. Based on known clinical use, thyrotropin alfa is a recombinant form of human thyroid-stimulating hormone (TSH), used clinically to stimulate thyroid follicular tissue via the TSH receptor — supporting post-surgical monitoring of thyroid cancer patients rather than treating the cancer itself.
There is no established mechanistic pathway connecting TSH receptor activation to migraine pathophysiology, which is primarily driven by the trigeminovascular system and CGRP signaling. The disease pair (thyroid tissue stimulation vs. migraine) has no obvious pharmacological or anatomical overlap, and the evidence pack explicitly flags this as a prediction lacking a plausible mechanistic basis.
Given the absence of any supporting clinical trials or literature specific to this drug-disease pair, this prediction should currently be regarded as a computational signal only, not a clinically actionable hypothesis.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Note: A related TxGNN prediction for “migraine with or without aura, susceptibility to” returned 20 PubMed hits, but all concerned shared epilepsy–migraine genetic susceptibility mechanisms (e.g., SCN1A, MTHFR C677T polymorphisms, neuroinflammation) with no mention of thyrotropin alfa or TSH-related pathways. These were assessed as an embedding-similarity artifact rather than direct drug-disease evidence and are not included above.
Denmark Market Information
Thyrotropin alfa currently has no registered marketing authorisations in this dataset (0 licenses, market status: Not marketed). No product-level information is available to tabulate.
Safety Considerations
Please refer to the approved Summary of Product Characteristics (SmPC) for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction is evidence level L5 (model prediction only) — no clinical trials, no supporting literature, and no identified mechanistic rationale link TSH receptor activation to migraine pathophysiology. There is currently no basis to advance this candidate.
To proceed, the following is needed:
- Confirmed mechanism of action (MOA) data for thyrotropin alfa (currently a data gap)
- Danish/EU product label warnings and contraindications (currently a data gap; blocking for safety pre-assessment)
- Preclinical or mechanistic studies exploring any TSH–trigeminovascular/CGRP pathway interaction
- Dedicated clinical trial or case-level evidence in migraine populations before any further evaluation
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.